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Abstract
Background Duchenne muscular dystrophy (DMD) is a severe X-linked neuromuscular childhood disorder that causes pro-
gressive muscle weakness and degeneration and results in functional decline, loss of ambulation and early death of young 
men due to cardiac or respiratory failure. Although the major cause of the disease has been known for many years—namely 
mutation in the DMD gene encoding dystrophin, one of the largest human genes—DMD is still incurable, and its treatment 
is challenging.
Methods A comprehensive and systematic review of literature on the gene, cell, and pharmacological experimental therapies 
aimed at restoring functional dystrophin or to counteract the associated processes contributing to disease progression like 
inflammation, fibrosis, calcium signaling or angiogenesis was carried out.
Results Although some therapies lead to satisfying effects in skeletal muscle, they are highly ineffective in the heart; there-
fore, targeting defective cardiac and respiratory systems is vital in DMD patients. Unfortunately, most of the pharmacological 
compounds treat only the symptoms of the disease. Some drugs addressing the underlying cause, like eteplirsen, golodirsen, 
and ataluren, have recently been conditionally approved; however, they can correct only specific mutations in the DMD gene 
and are therefore suitable for small sub-populations of affected individuals.
Conclusion In this review, we summarize the possible therapeutic options and describe the current status of various, still 
imperfect, strategies used for attenuating the disease progression.
Keywords Duchenne muscular dystrophy · DMD · Gene therapy · Cell therapy · Induced pluripotent stem cells · CRISPR/
Cas9
Duchenne muscular dystrophy: an overview
Duchenne muscular dystrophy (DMD, OMIM#310200) 
is a progressive, incurable, X-linked genetic disease that 
affects 1 in 5000–6000 boys. The disease is caused by the 
lack of functional dystrophin, due to over 7000 patient-spe-
cific mutations in DMD, one of the largest human genes 
containing 79 exons and approximately 2.4 million bp [1, 
2]. Interestingly, in healthy skeletal muscle, dystrophin 
accounts for only 0.002% of total muscle protein, but its 
absence leads to tremendous detrimental effects on muscle 
functionality [3]. The protein links the actin cytoskeleton to 
the extracellular matrix in muscle fibers by forming interac-
tions with subsarcolemmal actin and the large oligomeric 
dystrophin–glycoprotein complex (DGC) and regulates the 
proper functioning of muscle fibers (Fig. 1). The absence of 
dystrophin weakens the link between the sarcolemma and 
the actin cytoskeleton, resulting in membrane instability 
and muscle cell death. DGC is required, among others, for 
maintaining calcium  (Ca2+) homeostasis [4] and for proper 
neuronal nitric oxide synthase (nNOS) activity and NO sign-
aling muscle cells [5–7]. When DGC assembly is impaired, 
the increase in intracellular  Ca2+ ion concentration acti-
vates  Ca2+-dependent proteases, such as calpain and various 
chemokines and cytokines. This results in the continuous 
cycles of muscle degeneration and regeneration, the activa-
tion of satellite cells (muscle stem cells, mSCs), accumula-
tion of inflammation, fibrosis, and increased oxidative stress, 
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and leads to progressive muscle weakening and loss of mus-
cle mass and function. Mislocalization of nNOS at the sar-
colemma and disturbed NO homeostasis leads to impaired 
muscle blood flow and severe muscle fatigue. Additionally, 
DGC, by providing a scaffold for different proteins, plays a 
crucial role in numerous signaling pathways [1]. Of note, 
recent studies have also indicated that perturbations in other 
processes, such as mitochondrial signaling, autophagy, and 
angiogenesis, contribute to DMD progression [8]. These 
complications may be visible not only in the skeletal and 
cardiac muscles of DMD patients but also in the frequently 
used murine (e.g., mdx mice [9–11]) and canine (e.g., golden 
retriever muscular dystrophy; GRMD [12, 13]) models of 
DMD.
DMD patients can be diagnosed upon a thorough clinical 
evaluation, involving a patient’s detailed history, and spe-
cialized tests including biochemical analysis [e.g., elevated 
serum creatine kinase (CK), a marker of muscle necrosis 
[14]] and molecular genetic testing for dystrophin mutations. 
Various factors, such as proteins [e.g., lactate dehydrogenase 
(LDH)], lipids and metabolites (e.g., fatty acids, carnosine, 
taurine, and creatine), microRNAs (e.g., miR-1, miR-31, 
miR-133a, and miR-206), and genomic factors (e.g., latent 
TGFβ-binding protein 4—LTBP4 genotype) (reviewed in: 
[15]), may be helpful in DMD diagnosis; however, they are 
not specific. The potential applicability of serum levels of 
matrix metalloproteinase 9 (MMP-9), myostatin (GDF-8), 
and follistatin as non-invasive biomarkers was also sug-
gested [16]. The age of onset and the rate of decline may 
vary among DMD boys; however, the first signs of motor 
impairment and difficulty in walking are observed between 
1 and 3 years of age. In most cases, rapid disease progression 
and muscle-weakening occur between the ages of 10 and 14, 
and by age 20, affected individuals already begin to suffer 
from respiratory and cardiac failure, which leads to death in 
the 2nd or 3rd decades of their life [17].
Respiratory muscle weakness and decreased pulmonary 
function with a high incidence of respiratory infections are 
serious problems in DMD patients. The common standards 
of care include frequent respiratory function assessments as 
well as the use of respiratory assist devices and non-invasive 
ventilation (NIV), which decreases the risk of hypoventi-
lation events and improves the quality of life. However, 
improving the management of the devastating consequences 
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Fig. 1  Complications in DMD. Various mutations in the DMD gene 
lead to dystrophin deficiency. A lack of functional dystrophin causes 
sarcolemmal disruption and calcium channel activation by mechani-
cal stress. In turn, increased intracellular calcium level activates the 
release of calcium-dependent proteases and chemokines/cytokines, 
causing muscle degeneration, and necrosis. Other processes, includ-
ing the activation of satellite cells (muscle stem cells, mSCs), 
impaired regeneration, increased inflammation, altered autophagy, 
and insufficient angiogenesis as well as augmented fibrosis are the 
hallmark of the disease. Progressive muscle weakening, together with 
respiratory and cardiac complications, leads to patients’ death in the 
2nd to 3rd decades of their life. DGC dystrophin–glycoprotein com-
plex
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of skeletal muscle and pulmonary dysfunctions and the 
prolongation of life expectancy may lead to the appearance 
of cardiac problems associated with dystrophinopathies 
(Fig. 2). Of note, the incidence of dilated cardiomyopathy, 
characterized by left-ventricular (LV) dilation and decrease 
of the wall diameter resulting in a reduction in the cardiac 
ejection fraction [18], increases with age and more than 90% 
of young DMD men over 18 demonstrate evidence of cardiac 
dysfunction [19]. Additional cardiac complications includ-
ing conduction and electrocardiogram (ECG) abnormali-
ties like atrial and ventricular tachycardias as well as atrial 
arrhythmias may contribute significantly to DMD patients’ 
morbidity and mortality (references in [18–21]).
In cardiomyocytes, dystrophin exerts the same functions 
as in skeletal muscle cells; therefore, a lack of dystrophin 
results in increased cardiomyocyte structural vulnerabil-
ity, membrane instability, disruption in  Ca2+ homeostasis, 
augmented reactive oxygen species (ROS) production, and 
mitochondrial dysfunction [21]. In DMD heart, not only 
dystrophin-deficient cardiomyocytes exert impairment in 
their beating capacities—as dystrophin is expressed also in 
endothelial cells, vascular smooth muscle cells, and fibro-
blasts [22–25], and perturbations in the functioning of all 
those cells are responsible for cardiac complications. Of 
note, the functioning of dystrophic blood vessels is improper 
[22] causing decreased vascularisation of the muscle [23, 
24].
Heart problems in DMD patients can be undetected with-
out detailed examination [26, 27]. Many individuals have no 
classic symptoms of heart failure or they are unrecognized 
properly, as DMD individuals are mostly wheelchair bound 
and do not perform increased cardiac workload. Unfortu-
nately, it leads to a significant delay in their proper evalu-
ation and late initiation of pharmacological treatment [28]. 
However, to prevent the early onset of heart failure, it is 
suggested to start treatment before ventricular dysfunction is 
detected. In patients with end-stage heart failure, mechanical 
cardiac support by the use of various implantable devices 
including left-ventricular assist devices (LVADs) or pace-
makers may be helpful, although their usage creates ethical 
questions [18, 26, 29–31]. Additionally, heart transplantation 
might be a last resort, but the possible postoperative com-
plications, such as bleeding, arrhythmias, stroke, respiratory 
failure, and others, have to be considered [18].
DMD remains an incurable disease. Even though it was 
first mentioned in the early nineteenth century by Italian 
physicians Conte and Gioja and described in detail by 
French neurologist, Guillaume Duchenne in the 1860s fol-
lowed by many further studies [32], there is still no effective 
treatment available for all DMD patients. Although novel 
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Fig. 2  Progressive cardiovascular dysfunctions in patients with 
DMD. In early childhood, a normal ventricular function is detected, 
which progresses to end-stage heart failure demonstrated by systolic 
dysfunction and dilated cardiomyopathy. Steroids, angiotensin-con-
verting enzyme inhibitors (ACE inhibitors), angiotensin II recep-
tor blockers (ARB), beta-adrenergic receptor blockers (β-AR block-
ers), or mineralocorticoid receptor (MR) antagonists may be used to 
treat cardiac problems. Various implantable devices may be used as 
mechanical support as the disease becomes more severe. LV left ven-
tricular
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experienced a dramatic advance in the past 15 years, also 
in the context of DMD, only a small number of patients 
are amenable for treatment with mutation-specific drugs 
(described later). Therefore, there is a constant need to inves-
tigate novel approaches aimed at modulating the severity of 
the disease, at best. Discoveries in recent years have brought 
new strategies, and in this review, we will focus on the crit-
ical summary of the selected examples of the gene, cell, 
and pharmacological therapies suggested to be beneficial 
in experimental DMD models (Fig. 3). Currently, around 
280 clinical trials with different statuses (131 completed; 29 
terminated; 43 recruiting; 10 not yet recruiting; 10 enroll-
ing by invitation; 19 active, not recruiting; 2 suspended; 7 
withdrawn; 25 unknown status) are registered at www.clini 
caltr ials.gov. Selected trials are summarized in Table 1 and 
described in the ensuing chapters. However, it has to be 
underlined that registration of the trial at this database does 
not automatically indicate that the proposed treatment is safe 
and is supported by the strong scientific evidence. 
Gene‑based therapies
DMD is an attractive candidate for gene therapy, as it arises 
from single-gene mutations. It is believed that gene therapy 
will provide great opportunities for patients; however, so far, 
the approach has been highly challenging [33]. The optimal 
way of gene delivery, the appropriate (minimal) level of dys-
trophin expression, needed to stop disease progression and 
the prevention of immune reaction not only in response to 
gene therapy itself but also following the reintroduction of 
a gene whose product may be recognized as foreign by the 
immune system of DMD patients [34] are the most crucial 
factors which need to be optimized. As all dystrophic mus-
cles lack dystrophin, efficient gene therapy should allow the 
expression of a new dystrophin gene not only in limb mus-
cles but also in the diaphragm and the heart. The estima-
tion of how much dystrophin is required to speculate about 
the beneficial effects of the therapy is very challenging and 
questionable as various methods, measuring different out-
comes, have been used. It was shown that, in mdx mice, as 
little as 20% of the wild-type dystrophin level was effective 
in the prevention of disease progression when the creatine 
kinase level and fiber degeneration were assessed, but for 
cardiomyopathy treatment, this level should exceed 50% 
[35, 36]. In humans, it was speculated that around 30% of 
the wild-type dystrophin level is efficient [37]. However, 
the necessary amount might be dependent on the disease’s 
progression and individual condition of the patient. A recent 
report on dystrophin quantification listed several factors that 
may influence its level, including the structure and function-
ality of the new protein and the distribution of the dystrophin 
in muscle fibers. It has to be underlined that calculation of 
the amount of dystrophin may be greatly affected by the 
method used (and may even be misleading)—western blot 
analysis does not show if there is any dystrophin in all fibers, 
or higher dystrophin levels in some fibers, whereas immu-
nofluorescence gives information about localization, but is 
not a quantitative method [38].
Minidystrophin and microdystrophin 
overexpression using AAVs vectors
DMD is caused by recessive and monogenic genetic muta-
tions, mostly large deletions, duplications, rearrangements, 



















• Satellite cells (SCs)
• Muscle-derived stem cells (MDSCs)
• Myogenic progenitors derived from 
embryonic stem cells (ESCs) and induced
pluripotent stem cells (iPSCs) 
• Mesoangioblasts
• Pericyte-derived cells
• Bone marrow-derived stem cells (BM-
MSCs)
• Muscle-derived CD133+ cells
Fig. 3  Possible therapies in DMD treatment. Current strategies rely on gene, cell, and pharmacological-based therapeutic approaches. See details 
in the text
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aimed at the correction or improvement of muscle function 
by exogenous delivery of functionally engineered dystro-
phin gene constructs or augmentation of the endogenous 
locus have been broadly studied. Although different viral 
vectors can be used to deliver genes to muscle fibers, the 
recombinant adeno-associated virus (AAV)-based vectors 
are the most suitable in DMD gene therapies. The major 
advantages of AAV vectors include the ability to transduce 
non-dividing cells and possibility to provide the long-term 
expression of the delivered transgenes [39]. From several 
serotypes of AAV, serotypes 1, 6, 8, and 9 are extremely 
useful for DMD therapy as they exhibit a potent tropism for 
striated muscles [40]. For cardiac gene delivery by systemic 
vector administration, AAV9 was shown to be superior to 
other serotypes, including AAV8 [41].
The restoration of the dystrophin expression by gene 
transfer of full dystrophin coding sequence has been tested 
experimentally and in some clinical trials [42]. This is very 
challenging due to the size of the dystrophin gene, as the 
total dystrophin cDNA, counting 14 kb nucleotides cannot 
be packed in the majority of the available vectors. AAV vec-
tors have a limited carrying capacity as a 5 kb genome is 
considered to be the upper limit for a single AAV virion. 
Dystrophin is built of four major structural domains (Fig. 4): 
an N-terminal actin-binding domain (ABD1), and a central 
rod domain (containing ABD2) composed of 24 spectrin-
like repeats and 4 hinge domains (H1–H4). In the last H4 
domain, WW domain responsible for binding to part of 
the DGC is present. Finally, a cysteine-rich domain (CR) 
followed by a distal C-terminal domain that interacts with 
members of DGC at the sarcolemmal membrane is found 
in the full version of the protein. Of note, it has been found 
that some internal parts of the dystrophin sequence are dis-
pensable for protein functioning and a series of rod-trun-
cated and the C-terminal domain lacking dystrophin genes 
were proposed to be used instead of the full protein [33, 42, 
43]. This discovery has been possible thanks to elucidat-
ing the nature of DMD gene mutations in Becker muscular 
dystrophy (BMD), the milder and much rarer form of the 
dystrophin-dependent disease, in which the mutations result 
in loss of some exons, but do not abolish the dystrophin 
expression, as is the case in DMD [44]. Accordingly, it has 
been found that an artificially truncated version of dystro-
phin, lacking the internal part, like in BMD mutation, can be 
packed even in the small AAV vectors, creating the chance 
for the in vivo gene therapy strategies [18, 42]. Therefore, 
the functional but internally deleted “mini”- dystrophin 
[45] and “micro”- dystrophin [46] constructs to facilitate 
gene transfer have been established. Of note, around 40 
constructs of microdystrophin have been tested in animal 
models (reviewed in: [47]). However, the clinical efficacy 
of so far performed studies is far from expected, and this 
is, among others, due to the large mass of the muscles to be 
transduced, difficulty in transducing the diaphragm and par-
ticularly the heart. One of the first clinical trials with micro-


















STRUCTURE AND ADDITIONAL INFORMATION 
Minidystrophin
Microdystrophin
1H1ABD1 H4NH2 CR CT COOH16 17 24 SGT-001
Hoffman et al. 1987 [3]
µDys-5R
Lai et al. 2009 [49]
Hakim et al. 2017 [50]
Ramos et al. 2019 [51]
23
1H1 2 3ABD1 H2 H4NH2 CR CT COOHΔR4–R23/ΔCT
Harper et al. 2002 [45]
24












Fig. 4  A comparison of full-length dystrophin and truncated forms—
minidystrophin and microdystrophin currently in use in clinical trials. 
The differences in the structure and additional information, includ-
ing the number of the clinical trial and the commercial name of the 
drug are shown. Domains within dystrophin are abbreviated as fol-
lows: ABD actin-binding domain, 1–24 spectrin-like repeats, H hinge 
domains, CR cysteine-rich domain, CT carboxy-terminal domain
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weight (vg/kg) or 1 × 1011 vg/kg injected to the biceps] in six 
patients with DMD conducted in 2006 by Mendell et al. at 
the Nationwide Children’s Hospital in Columbus, Ohio USA 
[34] showed a very low level of microdystrophin expres-
sion (~ 3–4 positive myofibers in one low-dose patient, 
and 1 positive myofiber detected in one high-dose patient 
at day 42). These results were far from the expected and 
the expression of the product was not sufficient for efficient 
therapy. However, recent paper summarizing the results of 
1 year, nonrandomized-controlled trial (called Study-101, 
NCT03375164) with microdystrophin gene therapy using 
AAVrh74 vector, isolated from lymph nodes of rhesus mon-
keys and sharing 93% amino acid identity to AAV8 (SRP-
9001; AAVrh74.MHCK7) in four young DMD patients 
[48], showed increased levels of dystrophin by 81.2% in the 
muscles without signs of severe adverse effects. Currently, a 
phase 2 randomized, double-blind, placebo-controlled trial 
with SRP-9001 known as Study-102 (NCT03769116) is 
ongoing (Table 1).
It has to be emphasised that in this and the other studies 
with viral overexpression of microdystrophin, the patients 
were simultaneously treated with corticosteroids to prevent 
an immune response against the viral vector. As the patients 
received a high dose for the first 30 days, followed by their 
standard-of-care corticosteroid dose, it cannot be excluded 
that the observed benefits may be the result of steroid treat-
ment as well. Similarly, Pfizer has conducted a phase 1b 
trial (NCT03362502) with AAV9 carrying a minidystrophin 
gene under the control of a human muscle-specific promoter 
(PF-06939926). This study, aiming to assess the safety and 
tolerability of this approach is ongoing; however, in 2020, 
Pfizer is going to perform a second, randomized, placebo-
controlled phase 3 study to further test PF-06939926. Simi-
larly, Solid Biosciences, created SGT-001 (NCT03368742), 
AAV9 vector containing the muscle-specific promoter and 
microdystrophin. This construct, known also as μDys5R 
microdystrophin, carries the R16/17 nNOS-binding domain 
and was shown to efficiently restore nNOS localization in 
dystrophic animals [49–51]. The trial has started in Decem-
ber 2017, and the patients, after receiving a single intrave-
nous infusion of SGT-001, have been monitored for approxi-
mately 2 years. Preliminary results indicated that low levels 
of microdystrophin were present in the muscles of the treated 
patients, and no serious adverse events were reported (https 
://muscu lardy strop hynew s.com/). Of note, recently Pfizer 
has announced that in addition to mild adverse events (AEs) 
including vomiting, nausea, decreased appetite, and pyrexia, 
in four out of nine patients, serious AEs were described. 
In one patient, strong immune reaction occurred [atypi-
cal hemolytic uremic syndrome (aHUS)-like complement 
activation, which required hemodialysis and treatment with 
the kidney drug—eculizumab] [52]. Similarly, in the trial 
performed by Solid Biosciences, a 7-year-old patient was 
hospitalized as decreased red blood cell count, acute kidney 
injury, and cardio-pulmonary complications were noted after 
receiving a higher dose of SGT-001. As a consequence, in 
November 2019, the trial was placed on clinical hold, and 
even after sending an explanation by the company in April 
2020, the Food and Drug Administration (FDA) responded 
by requesting further data and analyses relating to the manu-
facturing process (www.solid bio.com, [53]).
Utrophin replacement
One concern of dystrophin replacement therapy is related 
to the immune reaction in response to the newly generated 
dystrophin protein [34, 54]. Immunosuppressant drugs may, 
therefore, be necessary. However, another option is based on 
the upregulation of utrophin, the related protein that disap-
pears in a majority of human muscles after birth. Utrophin 
is a structural (~ 80% of homology) and functional autoso-
mal paralogue of dystrophin [55], expressed in developing 
muscles at the sarcolemma [56] and progressively replaced 
by dystrophin [57]. In adults, it is mostly expressed in the 
lung, kidney, liver, and spleen [58], neuromuscular junc-
tion, and myotendinous junction in mature muscles [59] 
and in the sarcolemma in regenerating myofibers [60]. 
Therefore, it was speculated that it might have activities 
redundant to dystrophin and was tested to compensate for 
the dystrophin deficiency. This idea is also supported by 
the observation that double dystrophin-utrophin knock-out 
mice demonstrated more severe muscle weakness and car-
diac abnormalities with reduced life expectancy than mdx 
mice being dystrophin-only mutant [61, 62]. On the other 
hand, the upregulation of utrophin in mdx mice (by cross-
ing transgenic mice expressing the full-length utrophin pro-
tein in skeletal muscle with dystrophin-deficient mdx mice) 
positively affected muscle morphology, fiber regeneration, 
and mechanical properties [63]. The mechanism exerted by 
utrophin may also rely on the positive effects on mitochon-
drial dysfunctions observed during dystrophy progression. 
Using dystrophin-deficient mdx/utrophin overexpressing 
Fiona (mdx/Fiona) transgenic mice, Kennedy et al. [64] 
have demonstrated that high levels of utrophin ameliorate 
the aberrant structure and localization of mitochondria as 
well as reduce oxidative stress.
Still, new possibilities to overexpress utrophin are sug-
gested. Utrophin is repressed by several microRNAs, includ-
ing let-7c and the strategy of applying an oligonucleotide, 
able to anneal to the utrophin 3′UTR and prevent let-7c bind-
ing, thereby upregulating utrophin expression was tested 
[65]. Mishra et al. have used oligonucleotide composed of 
2′-O-methyl modified bases on a phosphorothioate backbone 
(let7-SBOs) to evaluate its effectiveness in mdx mice. The 
intraperitoneal (i.p.) injection of let7-SBOs led to increased 
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expression of utrophin in diaphragm, gastrocnemius, and 
tibialis anterior muscles of 2-month-old mdx mice after 
1 month of treatment. The delivery of let7-SBOs was also 
able to improve the dystrophic phenotype in vivo as assessed 
by morphological and physiological properties of muscles 
(e.g., muscle weight, muscle damage, inflammatory cell 
infiltration, and fibrosis as well as specific force) [65].
An important advantage of utrophin delivery might be a 
minimal risk of the immune response which was reported 
after a high dose of the AAV-minidystrophin gene, for exam-
ple, in the canine model of DMD and GRMD dogs [66]. 
Song et al. [67] performed a series of experiments aiming 
to compare the effectiveness of miniaturized utrophin, deliv-
ered by AAVs to similarly constructed microdystrophin. Not 
only did it prevent muscle disease in newborn mdx mice, but 
it was evidenced that there was a lack of immune response 
in neonatal GRMD dogs and amelioration of dystrophic 
symptoms without inducing T-cell responses in adult dogs 
deficient in the entire dystrophin [67].
Although utrophin exerts beneficial effects and is used 
to compensate for dystrophin deficiency, it must be stated 
that both proteins differ in some functions. One of the most 
important may be that utrophin is not able to prevent func-
tional ischemia during muscle contraction, the effect exerted 
by dystrophin as a consequence of nitric oxide synthase 
(nNOS) anchoring to sarcolemma [49, 68]. Dystrophin binds 
microtubules to form a rectilinear lattice beneath the sarco-
lemma, whereas utrophin cannot [69]. Therefore, utrophin 
therapy is not able to correct subsarcolemmal microtubule 
lattice disorganization and was not effective when physical 
activity after mild exercise or torque production after in vivo 
eccentric contraction in dystrophin-deficient skeletal muscle 
was evaluated [69].
As those differences may have important clinical con-
sequences, a combination of utrophin upregulation with 
dystrophin-based therapies for DMD has to be considered. 
Guiraud et al. [70] using various strains of mice differing 
in the expression of dystrophin and utrophin as well as by 
combining utrophin overexpression and dystrophin restora-
tion with exon skipping (see “Exon skipping approach”) in 
dystrophic muscle have demonstrated the additive benefits 
of such treatment over mono-therapies. It led the authors 
to suggest that utrophin overexpression may be particularly 
beneficial in BMD patients who express a low level of dys-
trophin [70].
Not only is gene therapy under evaluation, but many 
pharmacological ways to upregulate utrophin are also being 
considered (see “The upregulation of utrophin by drug ther-
apy is a plausible therapeutic approach in the treatment of 
DMD”).
Exon skipping approach
Another form of genetic therapy relies on the application 
of antisense oligonucleotides (ASOs), which, by binding 
to the exon/intron boundary or by targeting intra-exonic 
regions, can cause the exon skipping, and restoring the 
reading frame, leading to the expression of a truncated but 
functional protein [71]. As discussed above, this approach 
relies on the observation of some BMD patients, carrying 
in-frame exonic deletions, giving a dystrophin product that 
is truncated but highly functional [72].
Chemically, phosphorodiamidate morpholino oligomers 
(PMOs), 2-O-methyl-modified RNA, and tricycloDNA anti-
sense are used, among other modifications [73], for such a 
purpose. Several compounds were tested in various DMD 
animal models [74] and even demonstrated satisfactory 
results in phase 2 clinical trials [75, 76] (Table 1). Etep-
lirsen (or EXONDYS 51; Sarepta Therapeutics) is a PMO 
skipping the exon 51 of DMD gene and allowing to restore 
the dystrophin expression lost by the deletion of exon 49/50 
(Fig. 5). Of note, skipping the exon 51 may be beneficial 
for a larger group of DMD patients with deletions ending at 
exon 50 or starting at exon 52 (e.g.,, 45–50, 47–50, 48–50, 
49–50, 50, 52, and 52–63) [77] and it is estimated to be used 
in approximately 13–14% of DMD boys [14, 78].
Unfortunately, it is still not clear whether the effective-
ness of eteplirsen is as it was initially claimed and quite big 
discrepancies in the level of dystrophin protein detected in 
patients undergoing this therapy were noted (mostly being 
the result of various methods used to assess the dystrophin 
level) [78]. An analysis of the results of clinical trials with 
eteplirsen (NCT01396239/NCT01540409) revealed that 
after 180 weeks of treatment, western blot-based quan-
tification showed 0.93% of dystrophin levels observed in 
healthy individuals, whereas dystrophin-positive fiber counts 
assessed by IHC were detected at 17.4% on average.
In addition to the controversial assessment of an increase 
in dystrophin in muscle biopsy specimens, there were many 
additional doubts from the DMD community about the way 
which the drug was developed, the initial trial performed on 
the small size group, and, finally, that there were no obvious 
advantages in the functional test, the 6-min walk distance 
(6MWD) test capacity, between patients who received etep-
lirsen and those initially given a placebo [79]. Anyway, the 
drug was conditionally approved by the FDA in 2016 but 
not by the European Medicines Agency (EMA); therefore, 
it is not marketed in Europe. Of note, the manufacturer is 
obliged to present the data from the next randomized trial 
before May 2021 and those results will determine whether 
the initial doubts were unfounded [79].
As indicated in Table 1, a leading company, Sarepta Ther-
apeutics, is actively working in the field of splice modulating 
ASOs. Recently, after positive results of phase 1–2 trials and 
1242 A. Łoboda, J. Dulak 
1 3
the ongoing phase 3 trial, the FDA approved another drug, 
called golodirsen (VYONDYS 53, SRP-4053). This ASO is 
predicted to be used in around 8% of DMD patients having 
a confirmed exon 53 amenable mutation. Casimersen (pre-
viously named SRP-4045), the morpholino antisense, after 
promising results from phases 2 and 3 trials (ESSENCE 
trial, NCT02500381), showing a significant mean increase in 
dystrophin protein in the casimersen-treated group, is going 
to be tested further in DMD individuals amenable to exon 
45 skipping in the phase 3 extension study (NCT03532542) 
by weekly intravenous infusions at 30 mg/kg for up to 
144 weeks (golodirsen-treated patients are also included 
in this trial). As an example of studies performed by other 
companies, the safety, tolerability, and clinical efficacy of 
NS-065/NCNP-01 (viltolarsen) in patients amenable to exon 
53 skipping is performed by NS Pharma. In contrast to other 
morpholino oligomers given intravenously, DS-5141b, an 
antisense oligonucleotide consisting of 2′-O,4′-C-ethylene-
bridged nucleic acids and 2′-O-methyl RNA, targeting exon 
45 is going to be injected subcutaneously (Table 1). On 25 
March 2020, the drug received its first approval in Japan 
[80], whereas, on 7 February 2020, the company announced 
that the FDA accepted its New Drug Application (NDA) 
seeking approval under Priority Review and the decision 
should be released in the third quarter (July–September) of 
2020. If accepted, it will be the next drug, after golodirsen, 
for the treatment of DMD in patients amenable to exon 53 
skipping in the USA, and globally.
The systemic therapeutic effects of this technology may 
be limited by the endosomal entrapment observed both in 
muscle and cardiac tissues. Moreover, Alter et al. have 
shown that its effectiveness in the heart is lower than in 
skeletal muscles, as even after a high-dose multi-injec-
tion delivery, the restoration of dystrophin expression was 
observed in different muscles, but not the cardiac tissue 
[81]. A lack of restoration of dystrophin expression in the 
heart, along with improved skeletal muscle function, may, 
paradoxically, exacerbate cardiomyopathy due to increased 
physical activity of DMD patients (this might be a general 
problem of therapies, which concentrate only on skeletal 
muscles without targeting cardiac tissue) [82]. Therefore, 
improved cardiac targeting/delivery of ASOs to the heart 
is a challenge for the future. Several strategies have been 
described recently, including chemical modifications and 
new formulations, like tricyclo-DNAs, nanoparticles, 
peptides, and polymers (reviewed in [20]). For example, 
conjugation of PMOs to peptides (PPMOs) enhances cell 
permeability and increases the expression of dystrophin in 
the hearts of dystrophic mice [83, 84].
Continuous development and modifications in ASO-
based therapy led to the suggestion of using cocktail ASOs 
or the multiple exon skipping (or multi-exon skipping) to 
restore the dystrophin mRNA open reading frame. Such 
a strategy might be potentially applicable to 80–90% of 
DMD patients in total, regardless of mutation type [85, 
86]. This interesting therapeutic approach for treating 
DMD was first tested in the canine X-linked muscular 
dystrophy (CXMD) dog model, harboring a splice site 
mutation in intron 6, leading to a lack of exon 7 in dys-
trophin mRNA. The approach, based on the multi-exon 
skipping of exons 6 and 8, led to the correction of the read-
ing frame and resulted in the truncated dystrophin expres-
sion in skeletal muscles [87]. Further studies showed that 
PPMOs cocktail designed to skip dystrophin exons 6 and 
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Fig. 5  Mode of eteplirsen action. In healthy individuals, dystrophin 
is produced, whereas in a DMD patient, deletion spanning exons 49 
and 50 create out-of-frame frameshift that introduces a premature 
stop codon and result in a lack of dystrophin production. In such 
patients, eteplirsen, the exon skipping ASO targeting exon 51 of the 
DMD gene can be used. After hybridization to pre-mRNA, it affects 
the splicing machinery to skip exon 51 from the mature mRNA tran-
script. This converts the out-of-frame into the in-frame transcript cod-
ing for a shorter but functional protein
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8 after four systemic administrations into CXMD dogs 
rescued dystrophin expression in the myocardium and 
cardiac Purkinje fibers and improved cardiac conduction 
abnormalities in the dystrophic heart [88]. Those results 
indicate the effective applicability of ASOs in both mus-
cle and cardiac DMD dysfunctions, hopefully as a routine 
treatment of DMD patients in the near future.
Readthrough therapy
So-called readthrough therapy relies on restoring dystrophin 
expression through the inhibition of translation termination 
of a nonsense mutation. One of the first compounds with 
such properties, tested in vitro [89] and in vivo, in mdx mice 
[90, 91], was gentamicin, the antibiotic able to read through 
a nonsense mutation. Those preclinical studies gave diver-
gent outcomes; however, several clinical trials for DMD 
with the use of aminoglycoside therapy were initiated. The 
results from the phase 1 study conducted on 16 subjects 
with documented stop codon mutations receiving weekly 
(n = 12) or twice weekly (n = 4) gentamicin for 6 months 
indicated an increase in the dystrophin expression is some 
patients, with the most significant level detected in three 
patients (13.0–15.4% of wild-type levels, the effect irre-
spective of the regimen and with independent concordance 
by immunofluorescent and western blot analyses). Of note, 
a statistically significant decrease in serum CK level after 
6 months of gentamicin treatment was detected. However, 
a crucial indicator of the improvement in the quality of life 
like muscle functioning was not changed [92].
Long-term administration of gentamicin is related to its 
ototoxicity and nephrotoxicity [93]. Therefore, gentamicin 
derivatives NB74 and NB84 with superior activities in terms 
of cell toxicity and readthrough efficiency over gentamicin 
have been tested in vitro [94]. Also another aminoglycoside 
antibiotic NPC-14 (arbekacin sulfate), an inhibitor of 30S 
ribosomal subunit, resulting in codon misreading and inhi-
bition of translation was evaluated in the so-called NORTH 
POLE DMD trial at Kobe University (NCT01918384).
The most promising drug restoring the expression of func-
tional dystrophin by reading through the premature nonsense 
stop signals on dystrophin mRNA is ataluren (3-[5-(2-fluo-
rophenyl)-[1,2,4]oxa-diazol-3-yl]-benzoic acid). It can 
be potentially used in individuals with a nonsense muta-
tion in the DMD gene (around 11% of boys). Bushby et al. 
described the result of a phase 2b study (NCT00592553) 
in which patients received ataluren orally three times daily 
for 48 weeks (10, 10, and 20 mg/ kg referred to as ataluren 
40 mg/kg/ day; or 20, 20, and 40 mg/kg, referred to as ata-
luren 80 mg/kg/day) or a placebo [95], (Table 1). Ataluren 
40 mg/kg/day treated patients performed better than placebo 
patients, in contrast to individuals receiving the higher dose. 
It indicates a bell-shaped dose–response relationship which 
was already suggested by phase 2 study (NCT00264888) 
[96]. Results from the phase 3 trial (NCT02819557) per-
formed in boys aged 7–16 receiving ataluren orally three 
times daily (40 mg/kg/day) for 48 weeks in comparison to 
placebo-treated patients did not show significant changes in 
6MWD. However, some effect of ataluren was noted in the 
prespecified subgroup of patients with a baseline 6MWD of 
300 m or more to less than 400 m [97]. Based on those and 
other studies (there are 16 clinical trials registered for ata-
luren and DMD), the drug has received conditional approval 
in the European Union [14, 98], but the same data were 
not sufficient to register it by the FDA. Currently, a long-
term observational study of ataluren (Translarna) safety and 
effectiveness in usual care is ongoing. The results from this 
post-approval safety study, intended to enroll approximately 
200 patients across ~ 60 care centres in Europe who will be 
followed for at least 5 years from their date of enrolment, 
should bring more information about the drug safety and 
effectiveness in routine clinical practice.
CRISPR/Cas9 gene editing as a promising tool 
for DMD treatment
In recent years, the CRISPR/Cas9 system has been adapted 
as a tool that can edit the genome of nearly any organism 
and repair various genetic defects, including also the cor-
rection of mutated DMD gene. Functional dystrophin gene 
restoration has been demonstrated by CRISPR/Cas9 editing 
in myoblasts differentiated from induced pluripotent stem 
cells (iPSCs) of DMD patients [99, 100] [described in more 
detail in “Generation of myoblasts from embryonic stem 
cells (ESCs) and induced pluripotent stem cells (iPSCs)”]. 
By delivery of CRISPR/Cas9 components (Cas9 mRNA, a 
sgRNA targeting the mutated exon 23, and an ssODN repair 
template) into the zygotes of mdx mice, it was demonstrated 
that CRISPR/Cas9-mediated editing (termed myoediting 
[101]) can successfully correct Dmd mutation by homology-
directed repair—HDR or by nonhomologous end-joining—
NHEJ and restore dystrophin expression [102]. In 2016, 
three separate groups published results demonstrating the 
usefulness of this method for the restoration of dystrophin 
expression in adult mouse models of DMD [103–105]. A 
similar study was performed later in dystrophic dogs [106] 
and recently, Moretti et al. [107] applied CRISPR/Cas9 gene 
editing in dystrophic pigs. In the above studies, CRISPR/
Cas9 components were delivered in vivo using AAV vectors 
with quite positive results [103–108], (Fig. 6). For exam-
ple, after i.p. injections of the AAV vector into neonatal 
mice, recovered dystrophin expression was present not only 
in abdominal muscles but also in the diaphragm and heart. 
When intravenous administration was performed in 6-week-
old adult mdx mice, prominent recovery of dystrophin was 
found in the cardiac muscle [103].
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These studies indicate the therapeutic potential of the 
CRISPR/Cas9 system in the DMD therapy and emphasize 
that a single systemic treatment can be directed to a large 
number of cardiomyocytes and, thus, has a protective effect 
on the heart. However, to increase the targeting efficiency 
of the CRISPR/Cas9 system, the usage of a higher dosage 
of AAV was proposed. El Refaey et al. [108] compared 
low (3 × 1011 vg/mouse) vs high dose (1 × 1012 vg/mouse) 
of systemic delivery of AAV-SaCas9/gRNAs in 3-day-old 
mdx/Utr+/− neonates. After 10 weeks of treatment, almost 
no dystrophin-positive fibers were detected in the low -dose 
group, whereas about 40% of cardiomyocytes were dystro-
phin positive in the high-dose treatment group. Moreover, 
the rate of heart fibrosis was potently decreased, whereas 
cardiac contractility was improved after in vivo genome 
editing [108]. Similarly, in the porcine DMDΔ52 model, a 
low dose (1–2 × 1013 virus particles per kg (vp/kg) coated 
with G2-AAV9-Cas9-gE51, sporadically transduced skeletal 
muscle specimens, whereas a high dose (2 × 1014 vp/kg) led 
to the prominent dystrophin protein expression in skeletal 
muscles, the diaphragm, and heart [106].
The concern on CRISPR/Cas9 editing, especially for 
therapeutic and clinical applications, is related to the high 
frequency of off-target activity [109, 110], including the risk 
for mutations at sites other than the intended. The repair of 
double-strand break-induced by CRISPR/Cas9 could also 
lead to large deletions and/or complex rearrangements [106, 
107]. Taking into account the possibility of pathogenic con-
sequences of CRISPR/Cas9 editing, recent studies have been 
aimed at evaluating the long-term effectiveness and safety of 
this therapy for DMD treatment. Xu et al. [108] have checked 
the outcome of myoediting (deletion of the exons 21–23 to 
restore the dystrophin reading frame) after 19 months of 
delivery of AAVrh74-SaCas9/gRNA into 3-day-old mdx 
pups. No serious adverse effects of CRISPR genome editing 
(including no signs of tumorigenesis) were observed when 
various organs were analysed. Moreover, the large dele-
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Fig. 6  CRISPR/Cas9 technology for myoediting. AAV-CRISPR/
Cas9 vectors have been used in mice, pigs, and dogs to correct DMD 
mutations through different strategies, including exon deletion, exon 
skipping, exon repairing, or exon insertion. In case of CRISPR/Cas9-
based exon skipping, the indel introduced by Cas9 allows skipping of 
the mutated exon during mRNA maturation. For more details on pos-
sible strategies and their mechanisms, consult the paper by Min et al. 
[100]
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heart samples. Of note, the beneficial effects like restored 
dystrophin expression and improved cardiac function were 
evidenced. Similar long-term experiments, assessing the 
effectiveness and safety of CRISPR/Cas editing, were per-
formed by Nelson et al. [109] and Hakim et al. [110]. Sys-
temic administration of a single dose of AAV-Cas9 in neo-
natal mice led to dystrophin protein expression 1 year after 
treatment [109], whereas an optimization (increase) of the 
gRNA vector dose resulted in a higher level of the total dys-
trophin transcript in comparison to untreated mdx mice and 
the improvement in cardiac electrophysiology and hemody-
namic parameters even 18 months after a single intravenous 
of CRISPR/Cas9 vector [110]. In the future, similar experi-
ments evaluating the long-term potency and safety issues 
should be performed on non-mouse models.
RNA interference
Although not frequently used, strategies utilizing the RNA 
interference approach have been described in the literature 
and even tested in clinical trials. The combined therapy, 
utilizing dystrophin upregulation through an exon skipping 
approach and RNA interference against the activin receptor 
type IIb (ActRIIB) [111]—the receptor for myostatin—or 
the soluble version of this receptor was tested in dystrophic 
animals [112, 113]. Myostatin, known also as growth dif-
ferentiation factor 8 (GDF-8), belonging to the superfamily 
of TGF-β signaling molecules, acting via specific trans-
membrane receptors, mostly ActRIIB was shown to play 
a role in DMD through regulation of muscle cell growth 
and differentiation [113]. Myostatin or ActRIIB inhibition 
via different tools (not only RNA interference but also exon 
skipping, anti-myostatin/ActRIIB antibodies, dominant-
negative myostatin/ActRIIB, pharmacological inhibition, 
etc.) has revealed beneficial effects on muscle mass and 
function in wild-type and dystrophic mdx mice (reviewed in 
[113]). In contrast, several reports did not find any improve-
ment after blocking myostatin/ActRIIB signaling in humans 
undermining the effectiveness of this therapy [114–116]. Of 
note, two clinical trials with ACE-031, a soluble form of the 
human ActRIIB, were terminated based on the preliminary 
safety data (Table 1). Similarly, the trials conducted with 
myostatin antibodies (performed by Roche—NCT03039686 
and Pfizer—NCT02907619, Table 1) also failed to meet the 
primary endpoint, arguing the usefulness of this strategy 
in DMD patients. However, in a recent study, Mariot et al. 
[117] have suggested that the limited effectiveness of anti-
myostatin approaches is related to low myostatin levels 
detected in DMD patients. A decreased mRNA level of the 
myostatin pathway in muscle biopsies, as well as low levels 
of circulating myostatin in several neuromuscular diseases, 
were found. Moreover, when the level of myostatin was 
compared in patients with and without cardiac symptoms, 
it turned out that DMD individuals with cardiomyopathy 
had significantly lower myostatin levels than patients with-
out heart problems [118]. Therefore, it was suggested that 
the inhibition of this pathway by an exogenous compound 
(monoclonal antibody or vector-mediated inhibition) does 
not lead to an improvement in phenotype and strongly limits 
the potential clinical efficacy of this approach. Interestingly, 
the myostatin level in mdx mice is at least 50 times higher 
than in human DMD individuals [118]. This could be one of 
the reasons for the differences in the reported effectiveness 
of anti-myostatin therapy in a mouse model of the disease 
[112, 113, 119, 120] and humans [114–116].
Dystrophin‑independent gene therapies
In addition to dystrophin-based therapies, other muscle-sta-
bilizing proteins, such as follistatin, GALGT2, and bigly-
can, have been tested as the experimental genetic treatments. 
Moreover, calcium regulation using AAV-SERCA and AAV-
nNOS gene transfer approaches has been conducted.
Several studies have shown the beneficial effects of 
myostatin inhibition through the utilization of gene therapy 
with follistatin (FS), a factor regulating muscle regenera-
tion [118, 119]. A one-time gene administration (1 × 1011 
AAV1-FS) to 3–4-week-old mdx animals resulted in long-
term effectiveness, found even after 2 years. Of importance, 
when similar treatment was performed in older mice (6.5 
months old), enhanced muscle strength was still observed. 
Before starting clinical trials, a similar strategy was tested 
in nonhuman primates. Kota et al. have shown the safety 
of intramuscular injection of AAV1 vector expressing the 
human FS344 transgene, which encodes the FS315 fol-
listatin isoform (AAV1-FS344) into cynomolgus macaque 
monkeys [118]. In another study, concomitant delivery of 
microdystrophin and follistatin [120] was much more effec-
tive in improving muscle force than sole therapy, even in 
old animals (600-day-old mdx mice). Those results support 
the usefulness of combination therapy with gene replace-
ment and muscle enhancement in DMD treatment. In 2015, 
results from a phase 1/2a follistatin gene therapy trial were 
published. In two cohorts of BMD patients, after intramus-
cular injection of 3 × 1011 vg/kg/leg or 6 × 1011 vg/kg/leg, 
an improvement in 6MWD was observed in four out of six 
analysed individuals and overall reduced endomysial fibrosis 
and centrally nucleated fibers indicated positive effects of 
the therapy [121]. However, to the best of our knowledge, 
the effects of such treatment on mitigating the DMD cardiac 
phenotype have not been investigated yet.
AAV virus serotype rh74 carrying the GALGT2 gene 
under the control of an MCK promoter (rAAVrh74.MCK.
GALGT2) was developed by Sarepta Therapeutics. The 
GALGT2 gene encodes glucosyltransferase capable of 
upregulating the expression of various surrogate genes and 
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proteins, including utrophin, agrin, laminin α4, laminin 
α5, integrin α7, and integrin β1. Moreover, it encodes β1, 
4  N-acetylgalactosaminyl transferase that glycosylates 
α-dystroglycan in skeletal muscle. Its overexpression was 
shown to have beneficial effects in mouse models of various 
dystrophies: in mdx mice [121], the dyW model for con-
genital muscular dystrophy [122], and the  Sgca−/− model for 
limb-girdle muscular dystrophy 2D (LGMD2D) [123]. Not 
only was skeletal muscle damage ameliorated by this ther-
apy, but it was found to have improved heart function and 
cardiac output in mice overexpressing GALGT2 in compari-
son to mock-treated animals. In treated mdx mice increased 
expression of utrophin protein and a higher glycosylation 
level of α-dystroglycan protein was determined in the car-
diac tissue [124]. These preclinical studies led to the conduc-
tion of a phase 1/2 clinical trial (NCT03333590) evaluating 
the safety and effectiveness of rAAVrh74.MCK.GALGT2 
delivery to lower limbs through the femoral artery using an 
intravascular limb infusion technique (ILI). The results are 
expected in November of 2021, after regular evaluation of 
the patients for up to 24 months. Further experiments have to 
be performed, but this strategy may be potentially successful 
in DMD of various origin (regardless of the mutation), as 
although it does not restore dystrophin, it recruits dystrophin 
surrogates to compensate for the lack of dystrophin and pro-
tect the cell membrane.
Biglycan is a small leucine-rich extracellular matrix pro-
tein that interacts with multiple components of the dystro-
phin complex including dystroglycan and sarcoglycan com-
ponents. Its non-glycanated form (NG-biglycan), able to 
induce the localization of nNOS and utrophin to the muscle 
membrane [125, 126], was evaluated in the dystrophic ani-
mal model. In mdx mice, the use of both recombinant bigly-
can [126], as well as biglycan in the form of gene therapy 
[118], resulted in improved structure and function of skeletal 
muscles with no sign of toxicity. Recombinant AAV8 car-
rying hBGN encoding human biglycan was intravenously 
injected into 5-week-old mdx mice. Not only did it decrease 
the disease biomarker, CK level, but the number of central 
myonuclei and the distribution of myofiber sizes, as well 
as motor functions, also improved. Following encouraging 
preclinical results, Tivorsan Pharmaceuticals manufactured 
a highly purified formulation of this ECM protein and was 
planning to initiate clinical trials with TVN-102 in early 
2017/2018; however, so far, no results are available.
As mentioned in “Duchenne Muscular Dystrophy: an 
overview”, neuronal nitric oxide synthase (nNOS) repre-
sents an important part of the DGC complex and dystrophin 
deficiency results in disturbed nNOS-NO signaling [5–7]. 
Accordingly, nNOS gene therapy was tested as a possible 
DMD treatment. Lai et al. [127] constructed AAV9 vec-
tors containing shortened nNOS coding sequence, namely, 
lacking a PDZ domain in the nNOS gene (ΔPDZ nNOS). 
Delivery of such vector to the heart of aged (∼14-month-old) 
mdx mice led to the improved heart function with reduced 
myocardial fibrosis, inflammation, and apoptosis evident in 
mice at 21 months of age. Not only NO signaling but also the 
homeostasis of  Ca2+ is imbalanced in dystrophic muscles. 
The increased cytosolic calcium may lead to myofiber death 
and muscle dysfunction and it may greatly affect the func-
tioning of cardiomyocytes. Therefore, the normalization of 
the calcium signaling in DMD as the treatment strategy has 
been proposed. One of the attempts is to overexpress sarco/
endoplasmic reticulum (SR) calcium ATPase (SERCA), a 
calcium pump that transports cytosolic calcium to the SR 
during excitation–contraction coupling. The benefits of 
such treatment have been demonstrated in various animal 
models of DMD. The disease was mitigated in both dys-
trophin mutant mdx mice and δ-sarcoglycan–null  (Sgcd–/–) 
mice after overexpression of both SERCA1a and SERCA2a 
isoforms (both isoforms are found in adult muscle; however, 
SERCA1 is selectively expressed in skeletal muscle, while 
SERCA2a is present either in skeletal or cardiac muscle) 
[128]. In this study, 3-day-old Sgcd–/– pups were injected 
either with  1010  viral particles of the therapeutic gene 
(AAV9-SERCA2a) or with the control vector (AAV9-GFP), 
and analysis performed 6 weeks later demonstrated attenu-
ation of dystrophic phenotype. Other studies have reported 
the beneficial effects of neonatal AAV2/6-SERCA1a overex-
pression in the diaphragm [129] as well as cardiac improve-
ments after AAV9-SERCA2a delivery to 12-month-old mdx 
mice (1 × 1012 vg particles/mice) [130]. Long-lasting effects 
of such therapy were studied by Wasala et al. [131], and 
the amelioration of cardiomyopathy and skeletal muscle 
protection was demonstrated after 18 months after a single 
systemic delivery of SERCA2a isoform (AAV9-SERCA2a; 
6 × 1012 vg particles/3-month-old mdx mouse). SERCA2 
was highly overexpressed in the heart and skeletal muscle 
causing an increase in SR calcium uptake, better physi-
cal performance, no signs of myocardial fibrosis, and the 
improvement in ECG and restoration of ejection fraction in 
treated dystrophic animals.
Cell therapies
The idea of cell-based therapies relies on the transplanta-
tion of cells expressing functional dystrophin obtained 
from an unaffected donor (allogeneic transfer) or a patient 
after ex vivo genetic modification. The ideal cells should be 
delivered systematically to affect not only limb muscles but 
also the heart and diaphragm; should cross the blood vessel 
wall and be able to easily reach the muscles from the blood-
stream (to avoid multiple intramuscular injections); should 
integrate into resident myocytes and self-renew to provide 
a long-term effect without inducing an immune response. 
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Several various cell populations have been studied until now 
(Fig. 3); however, the usage of some cells, including bone 
marrow-derived mesenchymal stem cells (BM-MSCs) and 
CD133 + progenitors [132–134], is questionable. Although 
their limited ability to differentiate into muscle cells was 
described [135], follow-up experiments showed that only a 
small number of the BM-MSCs were capable of contribut-
ing to muscle fiber formation (in comparison to controls 
where muscle‐derived myoblasts were implanted) [136]. 
This observation suggested that the therapies with satellite 
cells (SCs) and other muscle-derived stem cells (MDSCs) 
are superior as the cells are more suited to participating in 
new fiber formation. Moreover, mesoangioblasts, pericyte-
derived cells, and myogenic progenitors differentiated from 
embryonic stem cells (ESCs) and induced pluripotent stem 
cells (iPSCs) have been tested. Unfortunately, the promis-
ing results from in vivo studies with some of these cells 
were not recapitulated in human trials [137, 138], while the 
others, based on pluripotent stem cells, still await testing in 
clinical trials.
Myoblast and satellite cell transplantation
Satellite cells (SCs), mononuclear cells with low cytoplas-
mic content, expressing Pax7 transcription factor, are located 
between the basal lamina and sarcolemma of adult skeletal 
muscle fibers [139, 140]. At least a part of these cells is able 
to self-renew and the cells are considered bona fide muscle 
stem cells, able to form new muscle tissue. After activa-
tion (mostly in response to injury), quiescent SCs proliferate 
and differentiate into myoblasts, which fuse with each other 
or with existing myofibers to repair the damaged muscles. 
This ability suggests that SCs are perfect for the treatment 
of muscle loss or disease, including DMD.
One of the first studies performed in the late 1980s gave 
very promising results and demonstrated the feasibility of 
normal myoblast injections into the muscles of mdx mice 
to correct a biochemical defect [141]. Some other studies 
also detected the expression of dystrophin-positive fibers in 
dystrophic individuals after normal myoblast delivery [142, 
143]. Unfortunately, clinical trials did not bring optimistic 
results [144, 145]. Miller et al. [145] injected 100 million 
allogeneic myoblasts in the anterior tibial muscle of one leg 
and a placebo in the other leg of 10 DMD boys. Increased 
force generation was found in both legs, but dystrophin 
expression was detected only in three patients after 1 month 
and in one patient after 6 months. As cyclosporine was 
administered for 7 months after myoblast injection, these 
results indicate that improvement in muscle function was 
rather due to immunosuppressive drug treatment and was 
not related to the cell-mediated effect. The results of a study 
performed by Mendell et al. [144] were even less promis-
ing, although the general regimen was very similar to the 
previous study (110 million cells injected once a month for 
6 months to the biceps brachii muscles of one arm of each of 
12 DMD boys with the other arm serving as sham-injected 
controls receiving cyclosporine or a placebo). No improve-
ment in the muscle strength in the arm injected with myo-
blasts and dystrophin expression analysed by imunostain-
ing found in one patient at ~ 10% and less than 1% in three 
other patients cannot be considered as a positive outcome 
of the therapy. As the study by Miller et al. [145] suggested 
a beneficial effect of immunosuppression, the next attempts 
were performed to combine such treatment with an increased 
frequency of cell injections and/or higher cell numbers. Sev-
eral papers by Skuk et al. [146–148] have described the new 
protocol based on the so-called “high-density injection” (the 
number of injections varied between 25 and 200) together 
with tacrolimus immunosuppression, which resulted in even 
30% of the donor-derived dystrophin-expressing myofibers 
visualized by fluorescent immunodetection.
Unfortunately, the poor survival and limited migration of 
myoblasts in vivo indicate that they are not the best option 
for cell-based therapies. SCs could be good candidates; how-
ever, quick differentiation of human cells to myoblasts limits 
their regenerative potential [149].
Mesoangioblasts
Mesoangioblasts, vessel-associated progenitors, able to 
differentiate into muscle fibers [150] were tested in mouse 
[151] and canine model [152] of DMD. Although critically 
evaluated by Bretag [138], the original study showed that 
intra-arterial delivery of dystrophin-expressing mesoan-
gioblasts resulted not only in the recovery of dystrophin 
expression but also in the improved muscle morphology 
and function of dystrophic dogs [152]. This and other stud-
ies pointed out the important ability of mesoangioblasts to 
cross the blood vessel wall. Such an advantage over SCs 
and myoblasts, which need to be delivered directly into the 
muscle tissue to properly engraft, indicates that these cells 
are valuable therapeutic cells [153, 154].
An interesting approach was described by Tedesco et al. 
[155], who used a combination of a human artificial chromo-
some (HAC)-mediated gene replacement and transplantation 
with blood vessel-associated stem cells. Mesoangioblasts 
from dystrophic mice after genetic correction with a HAC 
vector containing the entire (2.4 Mb) human dystrophin gene 
were injected into mdx mice. The morphological and func-
tional amelioration of the dystrophic phenotype that lasted 
for up to 8 months after transplantation indicated the effec-
tiveness of HAC-mediated gene transfer. Another example 
of mesoangioblast modification utilizes PiggyBac transpo-
sons. This system was more efficient in terms of stable gene 
transfer to primary mesoangioblasts when compared to the 
transfection of plasmid vectors and it resulted in satisfactory 
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transgene expression when transplanted intramuscularly into 
dystrophic animals [156, 157].
Those and other studies suggested that mesoangioblasts 
could be a valuable approach for stem cell therapy for Duch-
enne patients. However, a phase 1/2a clinical trial performed 
on five DMD patients revealed dystrophin expression only 
in one individual. Moreover, magnetic resonance imaging 
documented the progression of the disease in four out of five 
patients. Additionally, this trial indicated problems with the 
safety of mesoangioblast infusion as one patient developed 
a thalamic stroke [158], limiting the potential use of this 
approach in clinics.
Generation of myoblasts from embryonic stem cells 
(ESCs) and induced pluripotent stem cells (iPSCs)
As indicated above, cell therapies still have not given the 
expected effects. Therefore, new possibilities based on pluri-
potent stem cells, such as embryonic stem cells (ESCs), may 
be taken into consideration. ESCs, derived from the inner 
cell mass of the pre-implantation blastocyst stage, can be 
differentiated into all three germ layers of the embryo [159]. 
Different protocols can be applied to obtain SCs from ESCs 
and one of them involves the conditional overexpression of 
the Pax7 transcription factor [160]. By the use of a doxy-
cycline-inducible lentiviral vector encoding Pax7 and after 
intramuscular transplantation of such modified progenitors 
to immunodeficient mdx mice, widespread engraftment, 
shown by a large number of myofibers expressing human 
dystrophin, was evident [160].
However, the ESCs’ approach raises ethical controversies, 
and because of law regulations, it is not allowed in many 
countries. Therefore, obtaining the desired cell type from the 
induced pluripotent stem cells (iPSCs) creates a new pos-
sibility also for DMD modelling. Described for the first time 
in 2007 by Shinya Yamanaka, the 2012 Nobel Prize winner, 
human iPSCs (hiPSC) are generated from easily accessi-
ble somatic cells by overexpression of defined transcrip-
tion factors (most often OCT4, SOX2, KLF4, and c-MYC) 
[161]. In therapeutic perspectives, patient-derived iPSCs 
can be genetically corrected, differentiated in vitro into, for 
example, muscle cells and such dystrophin-expressing cells 
administered to the patient without inducing an immune 
response.
Although very attractive, a limitation of this method 
is the way of delivery of iPSC-derived muscle cells. Till 
now, intramuscular administration is the most efficient way 
[162], but systemic delivery, if shown feasible, would pos-
sess several benefits, such as the reduction of the number of 
injections and the possibility to target not only selected limb 
muscles but also the heart and diaphragm.
iPSCs’ technology may be of particular interest when 
heart problems are evaluated. As mentioned earlier, dys-
trophin-deficient cardiomyocytes exert serious functional 
problems and dilated cardiomyopathy greatly contributes 
to the mortality of DMD patients [19]. Therefore, the 
understanding of cardiomyocytes functioning, as well as 
the correction of defective cardiomyocytes obtained from 
DMD patients, should be of great importance. However, 
it is difficult to model this pathology in vitro as cardiac 
tissue is highly inaccessible [163] and the collection of a 
heart biopsy is not a routine diagnostic procedure [164]. 
iPSCs differentiated to cardiomyocytes may help to solve 
these problems as it has been already demonstrated that 
patient-derived iPSCs-cardiomyocytes (iPSCs-CMs) reca-
pitulate the pathophysiological phenotype observed in sev-
eral cardiac diseases and may serve as a tool for investigat-
ing the molecular basis of a particular heart condition as 
well as for drug screening (reviewed in: [165]).
Cells of DMD patients have been reprogrammed to 
iPSCs, differentiated to the cardiomyocytes and skeletal 
muscle, and were shown to recapitulate the DMD pheno-
type [99, 166–168]. More important, even the very large 
DMD gene deletions in such cells can be corrected by the 
CRISPR/Cas9 editing strategy, generating isogenic cells 
[99, 168]. Such strategy was utilized by Lin et al. who used 
human DMD iPSCs corrected by TALENs and CRISPR/
Cas9 technology (through exon 45 skipping, frameshift-
ing, and exon 44 knocking) and differentiated to skeletal 
muscle cells. The expression of full-length dystrophin 
protein in corrected cells was evident [169]. However, a 
combination of gene editing with autologous iPSC-derived 
myoblasts remains to be tested in clinical trials.
The possibility of the generation of the isogenic cell 
line, differing only at the locus of interest, eliminates 
potential problems when comparing cells from vari-
ous patients and healthy donors, which may be related 
to genetic background, sex, and ethnicity of patients, as 
well as other characteristics. In the context of studying 
mechanisms of DMD progression, modifying the iPSCs 
from healthy donors to introduce mutation is a valuable 
tool. The method used in our study is based on the design 
of specific sgRNAs targeting sequences located upstream 
and downstream of exon 50 (as deletion of exon 50 is one 
of the most common mutations in DMD patients). This 
allows removing exon 50 of DMD in control iPSCs line, 
further differentiation to desired cell type, and the down-
stream analysis of control and dystrophic cells (Fig. 7).
Finally, in the future, iPSC-CMs can be applied for the 
treatment of DMD cardiomyopathy. Replacing damaged 
cardiomyocytes by CRISPR/Cas9 corrected autologous 
iPSC-CMs or allogeneic iPSC-CMs are the potential 
option in light of recent studies showing the improve-
ment of heart function after pluripotent stem cells derived 
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CMs transplantation in animal models of heart failure 
([170, 171], Stepniewski et al., submitted). However, this 
approach is medically and technically challenging, and 
will require to solve the problem of necessary immunosup-
pression (due to dystrophin and allogeneic cardiomyocyte 
immunogenicity) and risk of arrhythmia.
Other cells used in cell therapy for DMD
Various cell-mediated therapies for DMD have been tested 
in recent years; however, clinical trials with stem cells 
are limited and up until now use mostly bone marrow and 
human umbilical cord cells, whose usage for treatment of 
DMD may be highly disputable. Other candidates, but still 
under evaluation, are cardiosphere-derived cells (CDCs), 
claimed to be a cardiac progenitor cell population, tested in 
mdx mice and even in clinical trials of acquired and congeni-
tal forms of cardiomyopathy and in patients with heart fail-
ure and reduced ejection fraction [172, 173]. In mdx mice, 
intramyocardial delivery of CDCs improved not only the 
heart but also skeletal muscle structure and functions includ-
ing better exercise capacity and increased survival [174]. 
The authors suggest the modulation of Akt, Nrf2 and NF-κB 
signaling pathways by CDCs and CDCs exosome. Also, the 
so-called Halt Cardiomyopathy Progression (HOPE)-Duch-
enne trial was performed in 13 DMD individuals (mean age 
18.7 years) receiving systemic corticosteroid therapy and 
other cardioprotective drugs as well as allogeneic CDCs 
(CAP-1002) (Table 1, NCT02485938, [175]). The initial 
results showed improvement in regional cardiac and skeletal 
functions after one intracoronary delivery of CAP-1002, but 
further studies should give more information about this kind 
of therapy in DMD patients. However, in the light of contro-
versies and recent stringent studies falsifying the existence 
of cardiac stem cells [176–178], the scientific rationale for 
the described approach should be critically evaluated.
Other options (not requiring the stem/pluripotent stem 
cells) being tested include the generation of myoblasts 
directly from patients’ fibroblasts. The conversion of somatic 
cells (fibroblasts) into myogenic cells may be forced by the 
overexpression of the myogenic factor MyoD, and some 
studies showed fusing of such myoblasts with existing mus-
cle fibers in mice [179–181]. Ito et al. [182] have found that 
defined combinations of transcription factors (Pax3, Mef2b, 
and Pitx1 or Pax7, Mef2b, and Pitx1 in embryonic fibro-
blasts, and Pax7, Mef2b, and MyoD in adult fibroblasts) effi-
ciently reprogrammed murine fibroblasts into skeletal mus-
cle progenitor cells able to form dystrophin-positive mature 
Fig. 7  Generation of the 
isogenic iPSCs cell line with 
CRISPR/Cas9 technology for 
studying the mechanism of 
DMD. The design of sgRNA 
targeting sequences located 
upstream and downstream of 
exon 50 leads to its deletion 
and creation of the isogenic cell 
line differing only at this locus 
from the control human iPSCs 
line. Further differentiation to 
skeletal muscle cells, cardio-
myocytes, and endothelial cells 
allows the phenotypic com-
parison between normal and 
dystrophic cells Exon
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muscle fibers when transplanted into mdx mice. Lee et al. 
[183] described the method of murine fibroblasts conversion 
to induced myogenic stem cells (iMSCs), characterized by 
the effective differentiation into multinucleated myotubes 
and higher proliferation capacity than muscle-derived stem 
cells. It was demonstrated that the combination of four tran-
scription factors, Six1, Eya1, Esrrb, and Pax3, is critical to 
establish iMSCs [183]. Another strategy was proposed by 
Bar-Nur et al. [184]. iMSCs, generated by the combination 
of the transient MyoD transcription factor expression and 
small-molecule treatment (the cyclic AMP agonist forsko-
lin, the TGF-β inhibitor RepSox and the GSK3β inhibitor 
CHIR99021), were able to self-renew and expressed mark-
ers of muscle stem, progenitor, and mature cells. Finally, 
the cells were able to differentiate into dystrophin-positive 
myofibers in mdx mice and contribute to muscle regeneration 
in a serial injury model (barium chloride-induced injury in 
immunodeficient  Foxn1nu mice). More clinical studies with 
iMSCs are needed to fully check their application as a mus-
cle regenerative therapy for muscle-wasting DMD disease.
Pharmacological therapies
Many pharmacological compounds are under evaluation 
both in the mdx mice as well as in clinical trials, and they 
are used to fight against various processes contributing to the 
disease’s pathology. Not only are anti-inflammatory factors 
or utrophin upregulators examined, but compounds/drugs 
regulating calcium signaling dysregulation, increased oxi-
dative stress, mitochondrial dysfunction, accumulation of 
fibrosis, and defective angiogenesis are also under constant 
screening (Fig. 3). As several reviews describing in detail 
the pharmacological strategies used in DMD have been pub-
lished recently [185, 186], we will only present a summary 
of the achievements in this field (Table 1) and concentrate 
on the selected approaches.
Inhibition of NF‑κB signaling exerts positive effects 
in ameliorating dystrophic pathology
Glucocorticoids (GCs) acting as anti-inflammatory agents 
are frequently used to halt progressive muscle damage; how-
ever, they concomitantly exert many adverse events leading 
to, among others, weight gain, loss of bone density and oste-
oporosis, diabetes, and muscle atrophy [187]. Prednisone, 
prednisolone, and deflazacort, mostly through inhibition of 
NF-κB signaling, have been shown to exert long-term pro-
tective effects and serve as a gold standard for the treatment 
of DMD [188, 189]. To decrease possible side effects, Quat-
trocelli et al. [190] have suggested weekly (instead of daily) 
steroid treatment and found comparable protective effects of 
both regimens, but only less frequent administration did not 
elicit muscle atrophy. GCs have been tested in many clinical 
trials (Table 1) and recent studies suggest that these drugs 
may improve not only muscular but also cardiac functions 
in dystrophinopathies [191–193].
GCs act mostly as anti-inflammatory drugs. It has to be 
underlined that further studies, with new drugs, lacking 
unwanted secondary effects are still warranted. Vamorolone 
(previously known as VBP15) may be a good example of 
such a compound. This glucocorticoid analog investigated 
by ReveraGen has been shown to exert superior activities in 
comparison to standard GCs. Heier et al. [194] found that 
vamorolone-treated mdx mice exert increased grip strength 
and decreased inflammation whereas such treatment did not 
exert side effects observed with prednisolone (e.g., stunted 
growth of developing mice, and increased muscle fibrosis 
in skeletal or cardiac muscle). A phase 1 trial performed 
in healthy adults gave promising results as any pharmaco-
dynamic safety concerns, typical for GCs, were noted up 
to 20 mg/kg/day [195]. Recent results from the study per-
formed on 48 boys with DMD (aged 4 to  < 7 years, steroid-
naive), treated daily with different doses of vamorolone, 
showed efficacy and lack of serious side effects at doses of 
2.0 and 6.0 mg/kg/day in a 24-week-treatment period [196, 
197] (Table 1). Of importance, vamorolone, being a miner-
alocorticoid receptor antagonist and glucocorticoid receptor 
agonist, may also exert cardioprotective effects [198].
Pharmacological interventions targeting histone 
deacetylases
The degeneration of dystrophic muscles suggests that com-
pounds able to increase the regenerative potential of skeletal 
muscle and preventing the replacement with inflammatory 
infiltrate, and fibrotic and fat tissue may ameliorate disease 
progression. Interestingly, epigenetic modifiers might exert 
such beneficial effects through enhancement of the regenera-
tive potential of dystrophic muscles while preventing their 
degeneration. One of the examples of such regulators are 
histone deacetylases (HDAC) which catalyze the removal 
of acetyl groups from lysines within histone and nonhistone 
proteins. HDAC activity was shown to be upregulated in 
dystrophic muscles and the effectiveness of HDAC inhibi-
tors (HDACi) was demonstrated in mdx mice [199–201]. 
The mechanism of HDACi action may include an increase 
in the level of follistatin, a factor regulating muscle regenera-
tion [202]. As mentioned in “Dystrophin-independent gene 
therapies”, follistatin is known to decrease the expression 
of myostatin, an inhibitor of muscle fibers regeneration but 
may also act through pathways independent of the myostatin 
signaling cascade [203]. Initial studies evaluated the struc-
turally unrelated HDAC (drugs which were already used in 
clinical practice for different therapeutic indications)—tri-
chostatin A (TSA), valproic acid (VPA), and phenylbutyrate 
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(PhB)—and indicated that mostly TSA restores muscle func-
tion and morphology in dystrophic animals [199]. Another 
example of HDACi tested in mdx mice is suberoylanilide 
hydroxamic acid (SAHA). This compound was effective in 
the amelioration of disease progression at doses between 
0.6 and 5 mg kg/day delivered to mdx animals for 3 months 
[204]. Finally, the number of studies performed with another 
compound blocking the activity of HDAC, givinostat, led 
to phase 3 clinical trials (NCT03373968, NCT02851797). 
Givinostat was first evaluated in dystrophic mice, and in this 
model, its effectiveness was comparable or even better than 
TSA [201]. Reduced fibrotic scars and fatty infiltration, as 
well as a decreased inflammatory infiltrate, were observed 
in the muscles of mdx mice exposed to 5 and 10 mg/kg/
day of givinostat whereas a dose of 5 mg/kg/day led to a 
significantly better muscle performance assessed by an 
exhaustion treadmill test [201]. These data suggested the 
possible therapeutic options for this compound in humans; 
therefore, a phase 1 clinical trial was started in January 2013 
(NCT01761292). As summarized by Bettica et al. [205], 20 
DMD boys aged 7–10 years on stable corticosteroid treat-
ment were treated for ≥ 12 months with givinostat (25 mg 
BID to 37.5 mg BID, depending on the scheme). Although 
a functional benefit was not observed in this study (which 
may be related to the small sample size), the histological 
evaluation of muscle biopsy showed an increase in muscle 
fiber size, reduction of fibrosis, tissue necrosis, and fatty 
replacement. Givinostat has been granted an orphan drug 
designation (EU/3/12/1009) by the EMA for the treatment 
of DMD and the ongoing phase 3 trials, with an estimated 
enrollment of 313 participants (100 for NCT03373968 and 
213 for NCT02851797), are underway and will hopefully 
bring more data about the effectiveness of HDACi and the 
potential of long-term treatment in DMD patients.
The upregulation of utrophin by drug therapy 
is a plausible therapeutic approach in the treatment 
of DMD
As mentioned earlier, gene therapy aimed at utrophin over-
expression represents a valuable therapeutic strategy. Phar-
macological factors have been found to upregulate utrophin 
expression and act protectively in animal models of DMD. 
One of such utrophin modulator, ezutromid (SMT C1100), 
has been shown to be safe for healthy adult men [63]. Inter-
estingly, recent results from the phase 1b trial have under-
lined the importance of a proper, balanced diet and the role 
of milk supplementation for the better absorption of ezutro-
mid (as it is highly insoluble in water), resulting in higher 
systemic exposure in DMD patients [206]. However, based 
on the information from clinicaltrial.gov, a phase 2 trial with 
this compound (NCT02858362) was terminated due to a lack 
of efficacy (Table 1). Summit Therapeutics has developed 
other molecules (but belonging to the same series as ezutro-
mid) with protective effects demonstrated in mdx mice [207] 
and other compounds like nabumetone, which can modulate 
utrophin promoter, have been tested in vitro [208].
Utrophin modulation can be a promising therapeutic strat-
egy for all DMD patients irrespective of their dystrophin 
mutation. However, although a milder disease in mdx mice 
expressing utrophin suggests the crucial protective role of 
this protein, in DMD patients, who have naturally upregu-
lated the expression of utrophin, the diseases progress as 
well [18]. This might be caused by the fact that utrophin is 
not able to replace all symptoms of dystrophin deficiency 
as it lacks NO-binding site [68] and is not able to prevent 
functional ischemia during muscle contraction [69].
Regulation of cardiac dysfunction and hypoxia 
prevention may have an impact on DMD 
progression
DMD patients could benefit from heart-targeted therapies 
[191–193]. Angiotensin-converting enzyme inhibitors 
(ACEIs) may exert cardioprotective effects in DMD indi-
viduals [209] as angiotensin II acts as a destructive agent, 
promoting oxidative stress, heart fibrosis, and cardiomyocyte 
death [210]. A 10-year follow-up study revealed a signifi-
cantly higher survival rate after presymptomatic treatment 
with perindopril (ACEI) for 3 years [209]. It is recom-
mended to start therapy with ACEIs even before the onset 
of LV dysfunction [18]. Also, angiotensin receptor block-
ers (like losartan) can be used as an alternative to ACEIs 
to suppress the deleterious effects of angiotensin in heart 
failure [211]. Other drugs, used mostly as the second-line 
therapy in DMD patients already presenting signs of LV 
dysfunction, are beta-adrenergic receptors (β-AR) blockers 
[212–214]. Mineralocorticoid receptor (MR) antagonists 
such as eplerenone, which have not only cardioprotective 
but also anti-fibrotic effects, have also been considered [215] 
(Fig. 2).
A lack of dystrophin leads to mislocalization of nNOS, 
a part of the DGC complex, at the sarcolemma and subse-
quent reduction in nNOS mRNA and protein level [5], nNOS 
activity [6], and NO production [7] causing unbalanced mus-
cle oxygenation and a lack of protective effect against exces-
sive sympathetic vasoconstriction and leading to functional 
muscle ischemia when the dystrophic muscles are exercised 
[216]. The decrease in nNOS activity results in the downreg-
ulation of the activity of soluble guanyl cyclase (sGC) and 
decreased cGMP level. Therefore, factors inhibiting cGMP 
phosphodiesterase (PDE5) activity thereby prolonging the 
biological half-life of cGMP [217] may be of particular 
interest in the context of DMD treatment. Of note, inhibi-
tion of PDE5 activity (by, for example, sildenafil or tadalafil) 
was shown to alleviate the DMD phenotype, mostly through 
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the reduction of fibrosis [218] as well as the cardioprotective 
effects both in mdx mice and in the dog model [219]. Nelson 
et al. [220] have checked the effect of PDE5 inhibition on 
muscle ischemia and skeletal muscle blood flow. Research 
performed on ten DMD patients (receiving background 
therapy with GCs), compared to perfectly matched ten con-
trol male individuals showed attenuation of muscle ischemia 
and impaired functional sympatholysis by PDE5 inhibition 
[220]. However, a bigger study, performed on more than 
300 DMD patients divided into control and tadalafil-treated 
groups, revealed no effect of PDE inhibitor given in two 
different regimens in comparison to placebo-treated boys 
(all taking standard GCs) [221]. This controlled phase 3 
trial assessing the possible functional improvement (e.g., 
by measuring 6MWD and other motor functions) after once-
daily supplementation with PDE5 inhibitor for 48 weeks 
failed to show its protective effect (Table 1, NCT01865084). 
Further studies are needed to fully assess the possible posi-
tive outcome of tadalafil on both cardiac and leg muscle 
injury as several factors (including the age of patients, a 
scheme of exercise performed by the affected patients) may 
influence the final conclusions.
Pharmacological treatments have demonstrated some 
beneficial effects, but it is still not fully known if prophylac-
tic cardiac therapy should be applied to all DMD patients 
and/or what kind of combination of the cardioprotective 
drug should be used.
New modulators of DMD progression
Targeting angiogenesis in DMD
DMD is not only a muscle-specific disease, as dystrophin is 
also expressed in other cell types, including vascular smooth 
muscle cells and ECs [22, 222]. This suggests that blood 
vessel formation in DMD patients and the properties of these 
cells might be impaired.
Although contrasting data have been published regard-
ing the status of angiogenesis in mdx mice [23, 223], these 
data might be very much affected by, among others, the age 
of animals, as reviewed by us recently [8]. We have found 
diminished expression of angiogenic factors in adult mdx 
mice, including vascular endothelial growth factor (VEGF) 
and CD31 (Pecam1) [224]. On the other hand, it was dem-
onstrated that the overexpression of pro-angiogenic and pro-
myogenic VEGF in mdx mice led to a reduction of necrosis, 
increased regenerating fibers, and capillary density in the 
regenerating area [225]. Inhibition of VEGFR-1, a negative 
regulator of angiogenesis, overexpression of pro-angiogenic 
angiopoietin-1 (Ang1), or combined VEGF/Ang1 delivery 
has also been considered therapeutic possibilities (reviewed 
in [8]).
The role of heme oxygenase‑1 in DMD
Heme oxygenase-1 (HO-1, encoded by Hmox1 gene) is a 
cytoprotective enzyme that not only degrades heme to car-
bon monoxide (CO), ferrous iron (inducing the synthesis of 
protective ferritin) and biliverdin (subsequently converted 
into antioxidant bilirubin by biliverdin reductase), but also 
possesses pleiotropic, non-canonical functions (for review, 
see: [226–228]). HO-1 exerts antioxidant effects, regu-
lates apoptosis and autophagy, and has anti-inflammatory 
properties and pro-angiogenic functions (for review see: 
[226–228]). We have demonstrated the involvement of HO-1 
in VEGF [229, 230] and SDF-1-dependent angiogenesis 
[231], and its contribution to angiogenesis-related processes 
like tumorigenesis [232–235] and wound healing [236].
Recent studies performed by our group revealed the con-
tribution of HO-1 to DMD onset and progression. First, 
we have found that HO-1 plays an important role in mus-
cle (progenitor) cell biology. HO-1 may promote the pro-
liferation of myoblasts and muscle regeneration when the 
short-term expression is evaluated [237]; however, long-
term expression leads to decreased differentiation through 
the modulation of muscle-specific microRNAs (myomirs) 
[238]. In both acute (cardiotoxin (CTX)-induced) [239] and 
chronic (mdx mice) [240] muscle damage models, a lack of 
HO-1 accelerated the pathological situation. Increased fibro-
sis, inflammation, muscle functioning (as demonstrated by 
the impaired running capacity), and disturbed and enhanced 
differentiation of SCs were evident in dystrophic mice with 
knock-out of HO-1 [240].
HO-1 also acts as an antioxidant factor. Antioxidants have 
been suggested as a potential treatment for DMD patients. 
Promising results were obtained when N-acetylcysteine 
(NAC) was evaluated in the mouse model of the disease 
[241, 242]; however, recent work by Pinniger et al. [243] 
revealed some adverse effects (reduced body, liver, and mus-
cle weight) of this treatment. Other studies with green tea 
extract or epigallocatechin-3-gallate (EGCG) known to exert 
antioxidant properties showed reduced necrotic fibers and 
increased resistance to fatigue of dystrophic muscles [244, 
245]. However, no beneficial outcome for patients treated 
with vitamin B, vitamin E, or penicillamine was observed 
in studies performed in the 1960s–1980s [246–248]. Gener-
ally, the results of clinical trials with antioxidants are rather 
disappointing (not only in the context of DMD) which may 
be caused by a difficulty in the choice of appropriate dose/
regimen of antioxidant treatment as well as many signaling 
pathways that are affected by non-specific factors [249].
Can statins be beneficial in DMD patients?
In 2015, Whitehead et al. [250] described the beneficial 
effects of statins in mdx mice. These findings were somehow 
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surprising, as statins, 3-hydroxy-3-methylglutaryl coenzyme 
A (HMG-CoA) reductase inhibitors, and drugs widely used 
for the treatment of hypercholesterolemia and reduction of 
atherosclerosis (reviewed in [251]) were mostly considered 
as compounds inducing skeletal muscle myopathy and rhab-
domyolysis [252, 253].
In contrast to these results, in studies performed by 
Whitehead et al., statins did not elicit any devastating effects 
on muscle function. On the contrary, decreased inflamma-
tion, fibrosis, and oxidative stress and accelerated muscle 
force were evident after a moderate daily dose of simvastatin 
[250]. Moreover, simvastatin treatment attenuated impaired 
autophagy which is known to contribute to DMD progres-
sion [254].
Statins are known to regulate angiogenesis [255–257] 
and exert cardioprotective effects [258]. Therefore, it is 
not surprising that their effect on cardiac complications in 
mdx mice was also evaluated. In addition to having protec-
tive effects on skeletal muscles, simvastatin also improved 
heart functions [259]. In older mdx mice (12 months old) 
spontaneously developing cardiomyopathy, simvastatin sig-
nificantly enhanced diastolic function as evidenced by echo-
cardiography and it also halted myocardial fibrosis. Improve-
ment in skeletal and cardiac muscle physiological functions 
by statins in mdx mice makes these drugs good candidates 
for clinical evaluation in DMD patients.
The results obtained by Whitehead et al. [250] are in 
contrast to the above-mentioned report about statin-induced 
myopathy. However, when a meta-analysis comparing the 
risk of the toxic statin-related muscle effect was performed, 
there was no difference when compared to patients treated 
with placebo [260]. The explanation for this discrepancy 
may be that statins are mostly prescribed to older patients 
(whereas DMD is a disease typically affecting very young 
boys) and the adverse effects of these drugs are aggravated 
by several factors, including exercise and female sex [261, 
262], both not relevant to DMD boys.
MicroRNAs in DMD pathology
Non-coding miRNAs target roughly 60% of human genes, 
emphasising their essential role in the regulation of many 
biological processes [263]. We have shown the contribu-
tion of numerous miRNAs in the differentiation of murine 
myoblast cells and SCs, and as mentioned earlier, we have 
examined their impact on muscle regeneration in a model 
of CTX-induced skeletal muscle injury and mdx mice [238, 
239].
A detailed analysis of the role of specific microRNAs in 
DMD revealed miR-200c to be responsible for muscle wast-
ing and myotube loss, most probably via a p66Shc-depend-
ent mechanism, increased ROS production, and oxidative 
stress acceleration [264]. Interestingly, our recent data [265] 
suggest that inhibition of miR-378, recognized as an impor-
tant mediator of differentiation and proliferation of myo-
blasts [266–268] and a regulator of skeletal muscle vascu-
larization [269], may attenuate dystrophic phenotype. On the 
other hand, we have found that miR-146a, known to diminish 
inflammation and fibrosis in different tissues by downregu-
lating the expression of proinflammatory cytokines, does 
not significantly affect the deleterious pathological events 
of DMD progression in mdx mice [224]. Another study 
pointed out the lack of beneficial effect of miR-92a inhibi-
tion on DMD progression in mdx mice despite the increased 
capillary density and tissue perfusion that was found after 
antagomir-92a [270].
Immunotherapy might help treat DMD
Recent studies by Zschüntzsch et al. [271, 272] provide 
evidence that human immunoglobulin G (IgG) treatment 
can improve DMD outcomes. The first trial analyzing the 
effects of 8-week i.p. injections of IgG on muscle perfor-
mance [271] was then repeated to see the long-term effec-
tiveness and also to analyse the possible benefits for heart 
degeneration [272]. In the second study, 3-week-old mdx 
mice following antibody treatment (IgG 2 g/kg body weight, 
administered monthly over 18 months by i.p. injection) had 
a lower serum level of CK as well as decreased expression 
of inflammatory markers and a significant reduction of the 
infiltration of T cells to various muscles in comparison to 
NaCl solution-treated controls. Moreover, the running per-
formance was better in IgG-injected animals. In addition, the 
cardiac phenotype was mitigated—fractional area shortening 
was improved, whereas cardiac fibrosis and the infiltration 
of T cells were decreased. This study in the mouse model 
is quite preliminary, but it may open a new direction for the 
treatment of DMD.
Future perspectives
Although numerous different targets/strategies and even 
clinical trials have been performed, DMD is still an incur-
able disease. Many questions have to be solved, including 
ones about the level of dystrophin necessary to have a posi-
tive effect on stopping DMD progression and especially the 
misleading information based on the method used. Moreo-
ver, both in the case of gene delivery and exon skipping 
approaches, the effectiveness of dystrophin restoration in the 
heart muscle is the greatest problem. There is even an appre-
hension that effective therapy in skeletal muscles, resulting 
in improved patient mobility, can increase the heart overload 
and actually worsen conditions [82]. Therefore, although 
restoration of dystrophin expression is the obvious aim 
to treat the disease’s primary cause, other approaches to 
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modulate the severity of the disease can be helpful. One 
can presume that the early detection of heart involvement 
may lead to introducing therapies which, like GCs, can sig-
nificantly postpone disease progression and improve the 
patient’s life. Therefore, there is an urgent need for better 
diagnosis of cardiac involvement in DMD patients. More 
importantly, the systemic markers routinely used for assess-
ing heart failure and cardiac damage, namely the increased 
serum brain natriuretic peptide (BNP) and troponin, are not 
good predictors in DMD patients, as their levels may not be 
significantly altered even in the case of heart damage [273]. 
Therefore, for the future, the identification of new, more spe-
cific markers is undeniably needed. Finally, more attention 
should be placed on the use of nutraceuticals and dietary 
supplements in DMD patients. Although vitamin D, taurine, 
creatine, curcumin, etc. can potentially attenuate inflamma-
tion, oxidative stress, and other pathological processes dur-
ing disease progression, they could also exert harmful effects 
either in high doses or when cross-reacting with other drugs 
which the patient is taking [274, 275].
We hope that more research experiments, including our 
attempts, and clinical trials will help in providing new thera-
peutic approaches, better patient selection, and stratification 
for future trials.
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